leisure time -WSS

leisure time

author：Wikipedia 2025-09-27 09:58:37 - browse：526

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Medicare Advantage isn’t working — for anyone

hotspot

WSS

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

2 officers injured in shooting in Orlando, police say

FDA scientists endorse Pfizer/BioNTech Covid

Cholera vaccine supplies dangerously low, outbreaks surging

FDA scientists endorse Pfizer/BioNTech Covid

Medicare isn't yet testing food as medicine

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

Are embryos people? Reproductive medicine's future depends on the answer

Trump demands the U.S. pay no more for drugs than other countries … again

How to ethically and practically extend health care to all

ChatGPT in medicine: STAT answers readers' burning questions

The a glaring gap in research on serious mental illness and primary care

How one medical school became remarkably diverse

A controversial new treatment promises to make little people taller

Wildfire smoke exposes gaps in outdoor worker protections

Florida officials tell state schools to teach AP Psychology 'in its entirety'

Wikipedia

Flint parents haunted by uncertainty, fears of lead poisoning

Alnylam reports growth in sales of rare disease treatments

The cancer stories no one wants to hear

Medicare isn't yet testing food as medicine

Elisabeth Bik tackles the widespread issue of research misconduct

'Null' research findings aren't empty of meaning. Let's publish them

leisure time

focus

hotspot

leisure time